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Sir,
With regard to your article Second Best Medical Ther-
apy (EJVES 24), we would like to thank the authors of
this paper who highlight a possible endemic failure of
vascular surgeons to institute best medical therapy
(BMT) in peripheral vascular disease (PVD) patients.
Following the preliminary findings of the Heart
Protection Study,1 we instituted an internal audit of
statin prescription in 75 consecutive patients suffering
from peripheral vascular disease. Our population
included both in and outpatient groups, we found
53% of our PVD patients (28% of inpatients, 72% of
outpatients) were on statin treatment, compared to the
others 38%. After presenting the initial findings and
instituting a change in local policy (taking into
account the findings of the Heart Protection Study2)
we undertook a second audit cycle. Overall an
improvement from 53 to 75% prescription rate was
achieved (88% of inpatients and 68% of outpatients)
in this cycle, an increase of 22%. Having found no
improvement in our outpatient statin prescription
levels over two audits we now await the closure of
this audit loop. We are working with our consultant
nurse specialist to improve the control of all risks for
PVD and will undergo a third audit cycle in February,
with specific regards to statin prescription. We did not
examine the control or investigation of other risk fac-
tors in this audit but might expect to find to a similar
deficiency in their treatment as was elucidated by
your study. We strongly agree that BMT should
receive more emphasis when managing PVD suf-
ferers. We recommend that all vascular units audit
and improve statin prescription rates following the
findings of the HPS.
J. D. Beard, J. Knowles and J. Quarmby
London, U.K.
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